The medication for p53 mutation in ovarian cancer needs to be chosen accordingly. Patients who are untreated and have a therapeutic response to platinum-based agents may be considered for treatment with platinum-containing chemotherapy in combination with bevacizumab. If a polyadenosine diphosphate ribose polymerase inhibitor (PARP) has been used and is sensitive to platinum-containing chemotherapy, platinum-containing chemotherapy in combination with bevacizumab; carboplatin, bevacizumab, and polyethylene glycolated adriamycin liposomes may be used. If a patient has been treated with bevacizumab, though may be sensitive to platinum-based chemotherapy, they can receive platinum-containing chemotherapy followed by maintenance therapy with a PARP inhibitor. Patients with advanced ovarian cancer may be treated with platinum-based chemotherapy in combination with bevacizumab, followed by maintenance therapy with olaparib. All of the above medications carry certain risks, and patients must use them under the guidance of a specialist.